FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3215213394> ?p ?o ?g. }

• W3215213394 abstract "Background: Tubercular uveitis (TBU) is commonly treated with anti-tubercular therapy (ATT) and corticosteroid or immunosuppressive adjuncts. The objective of this meta-analysis is to quantitatively evaluate the efficacy of ATT in TBU patients.Methods: In this systematic review and meta-analysis, a search of PubMed, EMBASE and Cochrane Library was conducted for articles on ATT outcomes in TBU published between 1 st January 2000 and 1 st August 2021. Study details, demographics, clinical features, investigations that led to a diagnosis of TBU, treatment regimen (ATT, corticosteroids and immunosuppressants), and information on target treatment outcomes was extracted independently by three reviewers. A meta-analysis of proportions was performed. Main outcome measures include inflammation recurrence; inflammation reduction; complete resolution of inflammation; improved visual acuity (VA); ability to taper corticosteroids to < 10 mg/day without inflammatory progression; use of adjunctive immunosuppressants while on ATT. This review is prospectively registered in PROSPERO (CRD42020206845)Findings: Forty-nine studies reporting data for 4,017 TBU patients were included. In comparative studies, the odds ratio (OR) of inflammatory recurrence was 0.33 (95%CI: 0.19-0.60) for TBU patients treated with ATT versus no ATT. For TBU patients treated with ATT, the pooled absolute incidences of inflammatory recurrence, inflammatory reduction, complete resolution of inflammation and of visual acuity improvement were 13% (n=310/2,216; 95%CI: 9-18), 81% (n=217/276; 95%CI: 62-95), 83% (n=1,167/1,812; 95%CI: 77-89), and 65% (n=347/542; 95%CI: 51-78) respectively. Corticosteroids were tapered to <10 mg/day without inflammatory progression in 91% (n=326/395; 95%CI: 78-99) of patients, 9% (n=121/1,376; 95%CI: 6-13) of whom were administered concomitant immunosuppressive agents alongside ATT.Interpretation: Treatment of TBU with ATT is associated with a high level of control or improvement of inflammation, followed by a two-thirds improvement in the risk of inflammatory recurrence in TBU patients; only one-seventh of TBU patients have recurrences during follow up. Visual acuity improved in most patients. However, more prospective studies with detailed reporting of ATT regimens, patient subgroups and outcomes are required to elucidate the effectiveness of ATT about other outcome measures.Funding: None to declare. Declaration of Interest: B.K.B, I.P., I.T., R.L.D.N., C.P. and V.G. report no conflicts of interest, financial or propriety, in the subject matter or materials discussed in this manuscript. J.H.K. is a consultant for Gilead Pharma, a company evaluating a treatment for non-infectious uveitis, and equity owner for Betaliq, a company developing an intraocular pressure-lowering treatment. R.A. is supported by a grant from the National Medical Research Council (NMRC), Singapore, for the Clinician Scientist Award (CSA) from 2020-2023. He has not received funding for his work in this publication." @default.
• W3215213394 created "2021-12-06" @default.
• W3215213394 creator A5006274430 @default.
• W3215213394 creator A5012009183 @default.
• W3215213394 creator A5020944672 @default.
• W3215213394 creator A5028660258 @default.
• W3215213394 creator A5043082246 @default.
• W3215213394 creator A5052634452 @default.
• W3215213394 creator A5057766177 @default.
• W3215213394 creator A5071992625 @default.
• W3215213394 date "2021-01-01" @default.
• W3215213394 modified "2023-10-16" @default.
• W3215213394 title "Anti-Tubercular Therapy in the Treatment of Tubercular Uveitis a Systematic Review and Meta-Analysis" @default.
• W3215213394 cites W1564384364 @default.
• W3215213394 cites W1976463178 @default.
• W3215213394 cites W1980202481 @default.
• W3215213394 cites W1990426006 @default.
• W3215213394 cites W1996066339 @default.
• W3215213394 cites W1996797658 @default.
• W3215213394 cites W2001724946 @default.
• W3215213394 cites W2006687015 @default.
• W3215213394 cites W2009767207 @default.
• W3215213394 cites W2019797684 @default.
• W3215213394 cites W2023279401 @default.
• W3215213394 cites W2043698180 @default.
• W3215213394 cites W2055484404 @default.
• W3215213394 cites W2063908629 @default.
• W3215213394 cites W2077683688 @default.
• W3215213394 cites W2081542063 @default.
• W3215213394 cites W2084621800 @default.
• W3215213394 cites W2088935730 @default.
• W3215213394 cites W2095753218 @default.
• W3215213394 cites W2099876751 @default.
• W3215213394 cites W2100166871 @default.
• W3215213394 cites W2106693567 @default.
• W3215213394 cites W2132426057 @default.
• W3215213394 cites W2134001138 @default.
• W3215213394 cites W2139499737 @default.
• W3215213394 cites W2154585393 @default.
• W3215213394 cites W2161794558 @default.
• W3215213394 cites W2162356941 @default.
• W3215213394 cites W2164625752 @default.
• W3215213394 cites W2164837478 @default.
• W3215213394 cites W2295099185 @default.
• W3215213394 cites W2468996569 @default.
• W3215213394 cites W2546786014 @default.
• W3215213394 cites W2560786075 @default.
• W3215213394 cites W2583491643 @default.
• W3215213394 cites W2600724517 @default.
• W3215213394 cites W2600788273 @default.
• W3215213394 cites W2726110339 @default.
• W3215213394 cites W2758888571 @default.
• W3215213394 cites W2760888328 @default.
• W3215213394 cites W2767182178 @default.
• W3215213394 cites W2771636860 @default.
• W3215213394 cites W2773795102 @default.
• W3215213394 cites W2782760404 @default.
• W3215213394 cites W2793394085 @default.
• W3215213394 cites W2794754833 @default.
• W3215213394 cites W2886639911 @default.
• W3215213394 cites W2900262175 @default.
• W3215213394 cites W2960996415 @default.
• W3215213394 cites W2971704583 @default.
• W3215213394 cites W3037163124 @default.
• W3215213394 cites W3119465813 @default.
• W3215213394 cites W3127743606 @default.
• W3215213394 cites W3159002700 @default.
• W3215213394 cites W4211157605 @default.
• W3215213394 cites W4235982599 @default.
• W3215213394 doi "https://doi.org/10.2139/ssrn.3938018" @default.
• W3215213394 hasPublicationYear "2021" @default.
• W3215213394 type Work @default.
• W3215213394 sameAs 3215213394 @default.
• W3215213394 citedByCount "0" @default.
• W3215213394 crossrefType "journal-article" @default.
• W3215213394 hasAuthorship W3215213394A5006274430 @default.
• W3215213394 hasAuthorship W3215213394A5012009183 @default.
• W3215213394 hasAuthorship W3215213394A5020944672 @default.
• W3215213394 hasAuthorship W3215213394A5028660258 @default.
• W3215213394 hasAuthorship W3215213394A5043082246 @default.
• W3215213394 hasAuthorship W3215213394A5052634452 @default.
• W3215213394 hasAuthorship W3215213394A5057766177 @default.
• W3215213394 hasAuthorship W3215213394A5071992625 @default.
• W3215213394 hasConcept C118487528 @default.
• W3215213394 hasConcept C126322002 @default.
• W3215213394 hasConcept C16005928 @default.
• W3215213394 hasConcept C17744445 @default.
• W3215213394 hasConcept C189708586 @default.
• W3215213394 hasConcept C199539241 @default.
• W3215213394 hasConcept C2776194053 @default.
• W3215213394 hasConcept C2779473830 @default.
• W3215213394 hasConcept C71924100 @default.
• W3215213394 hasConcept C95190672 @default.
• W3215213394 hasConceptScore W3215213394C118487528 @default.
• W3215213394 hasConceptScore W3215213394C126322002 @default.
• W3215213394 hasConceptScore W3215213394C16005928 @default.
• W3215213394 hasConceptScore W3215213394C17744445 @default.
• W3215213394 hasConceptScore W3215213394C189708586 @default.
• W3215213394 hasConceptScore W3215213394C199539241 @default.
• W3215213394 hasConceptScore W3215213394C2776194053 @default.

• next